Early-stage non-small cell lung cancer (NSCLC)
Conditions
Interventions
Robot-Assisted Thoracoscopic Lobectomy Combined with Optimized ERAS Protocol Group:None
Sponsors
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Age 18–75 years, sex unrestricted. 2.Diagnosis of clinical Stage I–II non-small cell lung cancer (NSCLC) via imaging and/or histopathology, with surgical resection indicated. 3.Tumor location amenable to robotic-assisted thoracoscopic surgery (RATS) lobectomy. 4.Adequate cardiopulmonary function and other major organ functions to tolerate surgery and single-lung ventilation (in accordance with the perioperative surgical fitness criteria recommended by the European Society of Thoracic Surgeons). 5.Female participants of childbearing potential must have used an effective method of contraception for at least 1 month prior to screening and agree to continue contraceptive measures throughout the entire study period. 6. Provide a signed and dated informed consent form; 7. Commit to adhering to study procedures and cooperating with all study procedures.
Exclusion criteria
Exclusion criteria: 1.History of prior thoracic surgery. 2.Preoperative receipt of neoadjuvant therapy (e.g., chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc.). 3.Anticipated need for combined procedures such as pulmonary vessel or bronchial sleeve resection. 4.Inability to comply with the Enhanced Recovery After Surgery (ERAS) protocol (e.g., due to severe cognitive impairment, psychiatric disorders, or language communication barriers). 5.Participation in another clinical trial. 6.Pregnancy or lactation. 7.History of severe allergy to anesthetic agents used during surgery. 8.Presence of specified medical conditions or diseases that preclude study participation, including: Severe hepatic or renal dysfunction (Child-Pugh Class C, eGFR 1.5 and uncorrectable); Uncontrolled infection; Severe cardiac disease (recent myocardial infarction, unstable angina, New York Heart Association [NYHA] Class III–IV heart failure); 9.Long-term immunosuppressive therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total operative time (Robotic console time); | — |
Secondary
| Measure | Time frame |
|---|---|
| ;Recovery speed indicators;Oncological indicators;Economic indicators; | — |
Countries
China
Contacts
Public ContactRunsen Jin
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Outcome results
None listed